Benchmarking International Outsourcing Preferences
Prior to April 2024’s BIOSECURE Act, we surveyed decision-makers in clinical development, manufacturing, and supply chain roles at biotechs in North America and Europe to assess outsourcing strategies, focusing on attributes they seek in a partner, CDMO perceptions, and considerations around working with contractors in China. The data provided WuXi AppTec with a benchmark of how it is perceived compared to competitors in the CGT space, highlighted decision drivers influencing biotech companies when selecting a contract partner and helped WuXi refine its positioning in Western markets.
